Pharmaceutical company Takeda leverages machine learning, AI, and more to increase plasma supply and better serve patients
Imagine you’re a patient with a rare, life-threatening illness with limited treatment options. The treatment that works for you is a plasma-derived therapy. It’s complex to produce, taking up to a year. It also can be complicated to administer, sometimes taking an hour or more to receive your infusion. And the kicker is that the source material is limited. Hundreds of plasma donations—and sometimes over a thousand—are needed to make enough therapy for just one patient for one year.
Pharmaceutical company Takeda leverages machine learning, AI, and more to increase plasma supply and better serve patients
Imagine you’re a patient with a rare, life-threatening illness with limited treatment options. The treatment that works for you is a plasma-derived therapy. It’s complex to produce, taking up to a year. It also can be complicated to administer, sometimes taking an hour or more to receive your infusion. And the kicker is that the source material is limited. Hundreds of plasma donations—and sometimes over a thousand—are needed to make enough therapy for just one patient for one year. Advertorial
